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OBJECTIVES: Loss of muscle mass and/or physical performance, a condition commonly known as sarcopenia, is
prevalent in chronic obstructive pulmonary disease (COPD) and is associated with adverse outcomes. The aim of
this study was to investigate the association between functional performance and sarcopenia in COPD patients
classified by disease severity according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
METHODS: The study was a cross-sectional observational and the sample size consisted of 35 COPD patients
(69.24±1.54 years, 20 men). Physical performance was assessed with the timed up-and-go (TUG) test. Sarcopenia
was assessed according to the European Working Group on Sarcopenia in Older People criteria.
RESULTS: The frequency of sarcopenia was 20% and was more prevalent among individuals classified with
greater disease severity, GOLD III, n=4 patients (23%) and GOLD IV, n=3 patients (27%), p=0.83. The mean time
to complete the TUG test was 11.66±4.78 s. Binary logistic regression revealed an association between the TUG
test and sarcopenia adjusted by disease severity (OR=1.55, 95% CI: 1.03-8.23, p=0.04).
CONCLUSION: Our findings showed that worse performance in the TUG test leads to a substantial increase in the
chance of COPD patients presenting sarcopenia.
KEYWORDS: Lung Diseases; Hand Strength; Walking Speed; Sarcopenia; Physical Functional Performance.
’ INTRODUCTION
Chronic obstructive pulmonary disease (COPD) affects the
lungs primarily by limiting airflow, and in more advanced
stages of the disease, patients present dyspnea and reduced
exercise tolerance (1). COPD is considered a systemic disease
and is characterized by various extrapulmonary effects,
including systemic inflammation (2), comorbidities (3) and
skeletal muscle dysfunction, especially in the lower limbs (4).
These effects contribute to a reduction in functional capacity
(5) and impair the patient’s quality of life and ability to
perform activities of daily living (6). In addition, the lack of
infrastructure, social influences (7) and even the number of
hours for which daily oxygen therapy (with equipment that
limits the patient’s movements) is used can reduce the level
of physical activity during daily living, leading in turn to a
significant reduction in functional and exercise capacity in
these patients (8).
Sarcopenia is another systemic manifestation in COPD
(9,10). According to the European Working Group on
Sarcopenia in Older People, sarcopenia is probable when
low muscle strength is detected, and it is confirmed by the
presence of low muscle quantity or quality. Furthermore,
when low muscle strength, low muscle quantity/quality and
low physical performance are all detected, sarcopenia is
considered severe (11) and was recently recognized as an
independent condition by the International Classification of
Disease (12). In addition, as sarcopenia is strongly associated
with multiple negative outcomes in the elderly, an investiga-
tion of this condition in COPD patients is fundamental to
alert physicians for early diagnosis and treatment of loss of
lean muscle mass, preventing worse outcomes and poorer
quality of life (9,10).
The frequency of sarcopenia in COPD patients varies from
15% to 40% according to age and the method used to assessDOI: 10.6061/clinics/2019/e930
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muscle mass, such as dual-energy X-ray absorptiometry
(DXA) (9), bioimpedance analysis (10) and calf circumference
(10-17). To date, few studies (10,18) have examined sarcope-
nia in COPD with an emphasis on the loss of muscle mass
and physical performance. The results of these studies also
support an association between sarcopenia and systemic
inflammation, dyspnea (15), poor quality of life (10), poor
prognosis (9) and frailty (19).
However, to our knowledge, the association between
sarcopenia and the results of simple physical performance
tests, such as the timed up-and-go (TUG) test, have not
yet been investigated. Timed up and go test is reliable, valid
and responsive (20) and has been used with COPD patients,
as it can be performed in most healthcare settings. In our
study, we hypothesized that COPD patients with sarcopenia
might have worse performance in the TUG test when
adjusted by disease severity. The aim of this study was to
investigate the association between physical performance
and sarcopenia in COPD patients classified by disease
severity according to the GOLD criteria.
’ MATERIALS AND METHODS
The study was a cross-sectional observational and was
carried out between May 2016 and May 2017 following the
recommendations of the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) initiative
(21). The sample consisted of patients referred to a pul-
monary rehabilitation program at a university center in the
city of Curitiba in southern Brazil. After study approval by
the ethics committee of the local municipal department of
health (ref. no. 481.008/2013), potential participants were
contacted by telephone to schedule an assessment. Indivi-
duals who were considered eligible signed a voluntary
informed consent form that explained the aims, procedures,
possible risks and benefits of the study. Patients were
assessed at a physical therapy clinic or in their homes if
they were unable to attend the clinic. All assessments were
supervised by two previously trained physical therapists.
The inclusion criteria were as follows: being over 50 years
of age; having a diagnosis of COPD classified as stage II to IV
according to the GOLD criteria; having given up smoking at
least 6 months previously; being clinically stable (i.e., the
disease had been stable for at least 1 month); and not having
been in any physical rehabilitation or training program in the
previous year. Exclusion criteria were the presence of other
pulmonary diseases (e.g., asthma and pulmonary fibrosis) or
other incapacitating, severe or difficult-to-control nonpul-
monary diseases that could interfere with the tests.
Pulmonary function was assessed with a spirometer
(Microlab Spiro V 1.30, Micro Medical Ltd., Rochester, Kent,
England) using the American Thoracic Society guidelines
(ATS) (22) considering reference values established by Pereira
et al. (23) Severity of airway obstruction was classified accord-
ing to the GOLD criteria (GOLD II: 50% pVEF1 o80%;
GOLD III: 30% pVEF1 o50%; GOLD IV o30%) (1).
Primary Outcome
Physical performance was assessed with the TUG test
(24,25). In the TUG test, the patient got up from a chair (seat
height 45 cm) without using his arms, walked at a
comfortable, safe pace for three meters, returned to the chair
and sit down. The test was timed (in seconds) from the
beginning of the test to the moment the participant leaned
against the back of the chair again. TUG was first demon-
strated by the researchers after the patient performed the test
once to become familiar and then it was carried out again
for timing (24). A cutoff point of 11.2s was used to indicate
reduced functional performance (26).
Secondary Outcome
The presence of sarcopenia was investigated by evaluating
the handgrip strength (HGS), calf circumference and gait
speed test (11).
HGS was assessed using a Saehan hydraulic hand dyna-
mometer (Saehan Corporation – SH5001). The participant
was seated with his feet on the ground, hips and knees flexed
at 90o without any support for the arms, shoulders in
adduction with neutral rotation and one elbow flexed at 90o
with the ipsilateral forearm and wrist in neutral position.
Then, the patient was asked to perform three maximal
contractions with a 1-minute rest between each. The mean of
the grip strength measurements in kilograms for the three
attempts was used for analysis. Low HGS was defined as
HGS o30 kg for men and o20 kg for women (27).
Skeletal muscle mass was estimated based on calf circum-
ference and was measured in the most prominent region of
the dominant calf with the patient sitting and the hip and
knee flexed at 90o. A cutoff point of 30 cm was used to
indicate reduced skeletal muscle mass (28).
Physical performance was assessed using the GS test,
which was performed over 10 m, covered surface with
positions marked on the floor at 0, 2, 4, 6, 8 and 10 m.
Participants were positioned at the 0 m point and instructed
to walk in a straight line for 10 m after the command ‘‘Go’’
was given. The distance to cover the route was divided by
the time to give the mean (m/s). The test was performed
three times, and the best value was used for analysis. The
first and last 2 m were excluded to allow time for the patient
to accelerate and decelerate (29,30). Participants were asked
to walk at their normal pace, and no incentive was given to
avoid influencing the result (29,30). A cutoff point of 0.8 m/s
was used (31).
Statistical Analysis
Sampling was nonprobabilistic, and all the patients who
met the inclusion criteria in the study period were included.
However, a post hoc calculation using an effect size of
0.5 based on Cohen’s d and the sample size of 35 patients
showed a power of 91% to detect an association between
TUG and sarcopenia in patients classified according to
disease severity.
The Shapiro-Wilk test was used to test normality. The
groups were compared by one-way analysis of variance
(ANOVA) followed by Tukey’s post hoc test.
After adjustment of the results for disease severity
according to the GOLD criteria, binary logistic regression
was used to detect an association between the results of the
TUG test and the presence of sarcopenia according to disease
severity. A significance level of po0.05 was used. The data
were analyzed with Statistical Package for Social Sciences
(SPSS) version 21.0, and study power was calculated with
G* Power 3.1s.
’ RESULTS
Forty-five individuals with COPD were recruited, but only
35 of these were included in the study, as shown in Figure 1.
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The demographic, anthropometric, clinical and functional
characteristics of the patients are shown in Table 1. The
patients were seniors, and the majority were classified as
GOLD III (49%) or GOLD IV (31%).
Patients were divided according to their disease staging
(GOLD 2017) (01). There was no statistically significant dif-
ference between patients in terms of age (p=0.865), sex
(p=0.576) or BMI (p=0.064). Patients classified as GOLD IV
had significantly lower functional performance than GOLD
II (14.46±5.88 s vs 9.55±2.36 s) and III (14.46±5.88 s vs
10.62±2.81 s), as assessed with the TUG test (Figure 2).
The frequency of sarcopenia among the 35 patients was
20% (7 patients) and was greater among individuals
classified with greater disease severity, GOLD III = 4 patients
(23%) and GOLD IV = 3 patients (27%), p=0.82.
Binary logistic regression revealed an association between
a TUG time 411.2 s and sarcopenia when patients were
classified by severity of disease (OR=1.55, 95% CI: 1.03-8.23,
p=0.04).
’ DISCUSSION
In this cross-sectional study, sarcopenia was associated
with TUG performance after adjustment for disease severity,
indicating that when disease severity is considered, COPD
patients with worse TUG performance are more likely to
have sarcopenia. Up to one-third of COPD patients, even in
the early stages of the disease, have a loss of muscle function
in their limbs (25% less strength than controls) (32).
Previous studies have shown that the frequency of
sarcopenia is highly dependent on the method used for
assessment and can vary from 14% to 40% in COPD patients
(9,16,17). In our study, in which sarcopenia was considered
to be present when HGS o30 kg for men and o20 kg for
women with low muscle mass, i.e., calf circumference
o30 cm and severe sarcopenia with GS p0.8 m/s or TUG
411.2 s, we found a frequency of 20%, showing that low
muscle quantity/quality and low physical performance not
only affect the elderly but also have a high percentage among
patients with chronic respiratory diseases. Furthermore,
when we investigated the presence of sarcopenia in our
patients according to their disease staging, a greater fre-
quency of this condition among patients with more severe
COPD was found. A similar study found a higher frequency
of sarcopenia in GOLD III and IV patients (15% and 20%,
respectively) where patients with sarcopenia who were
significantly older and had more airflow obstruction and
reduced quadriceps strength, exercise capacity, functional
performance, subjective and objective physical activity
and health status compared with patients without sarco-
penia (10).
This difference between the results of the studies may be
because Costa et al. (9) used DXA, which is considered a gold
standard for diagnosing sarcopenia, whereas we used calf
circumference, gait speed and grip strength (33). Never-
theless, DXA often cannot be used in clinical practice because
of the high cost of the equipment and the need for trained
individuals to carry out the exam. The approach used in the
present study has the advantage in that it requires only
simple tools that can easily be used in clinical practice (e.g.,
a measuring tape).
Table 1 - Demographic, anthropometric, clinical and functional
characteristics of the sample.
Variable (n=35)
Age (years) 69.30±7.47
Sex F/M (n) 19/16
BMI (kg/m2) 24.17±5.51
Tobacco load (pack years) 42 [22-55]
FEV1 (% predicted) 37.93±13.64
FEV1/FVC 48.58±12.74
GOLD II / III / IV (n) 7/17/11
HGS (kg) 23.92±9.66
CC (cm) 34.04±4.61
GS (m/s) 0.90±0.32
TUG (s) 11.83±4.60
Data are given as the mean ± standard deviation or median
[interquartile interval]; F: female; M: male; BMI: body mass index; FEV1:
forced expiratory volume in the 1st second; FVC: forced vital capacity;
GOLD: Global Initiative for Chronic Obstructive Lung Disease; HGS:
hand grip strength; CC: calf circumference; GS: gait speed; TUG: timed
up-and-go.
Figure 1 - Data collection flowchart.
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Patients classified as GOLD IV had significantly lower
physical performance than GOLD II and III patients assessed
with the TUG test. Our GOLD IV patients completed the
TUG test in 14.29 s, substantially longer than the cutoff
adopted here and suggested by Mesquita et al., who showed
that this test is valid for assessing functional capacity in
COPD patients and that a test completion time of more than
11s indicates worse health (26). Haddad et al. proposed a
cutoff 42 s to identify COPD patients at high risk for
falls and reported a mean TUG time of 11.9 s in their study
(34). Both values are lower than the data found in the
current study.
Despite these findings, Haddad et al. did not identify a
relationship between TUG performance and spirometry
results or any differences between the TUG results of
patients among disease stages. However, most of the
patients were classified as GOLD I or II, unlike the patients
from our study, who were predominantly GOLD III or
IV (34).
The present study has several limitations. These include
the small number of participants, possibly favoring the
analysis of the stratification by the severity of the disease and
the fact that muscle mass was not assessed using the gold
standard. Despite the small sample, a post hoc calculation
revealed a power of 0.91, i.e., a 91% chance of detecting an
association between the results of the TUG and sarcopenia.
Furthermore, although DXA is more accurate and reliable, it
is expensive and difficult to use in clinical practice. Muscle
mass was therefore assessed by measuring calf circumfer-
ence, which is a simple clinical method, but not the only
criteria used to screen for sarcopenia, as grip strength, gait
speed and TUG were also assessed for diagnosis (35). Calf
circumference may be used to measure muscle mass as a
proxy for muscle quantity in settings where no other method
is available (11).
’ CONCLUSION
Our findings showed that a worse performance in the
TUG test increases the chance of COPD patients presenting
sarcopenia.
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